Literature DB >> 21302606

Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu).

Ary Serpa Neto1, Marcos Tobias-Machado, Marcelo Langer Wroclawski, Fernando Luiz Affonso Fonseca, Antonio Carlos Lima Pompeo, Auro Del Giglio.   

Abstract

The potential mechanisms involving the genesis and growth of androgen-independent prostate cancer include super-expression of the androgen receptor (AR), in an attempt to compensate for the low androgenic plasma levels and mutations of this specific receptor, which could determine resistance to anti-androgenic therapy. However, most advanced prostate tumors have no mutations or amplifications of the AR, suggesting a potential role of non-androgenic growth factors, including epidermal growth factor (EGF), transforming growth factor alpha, insulin-like growth factor (IGF-1) and fibroblast growth factor. More specifically, these factors, and their receptors like EGFR (HER-1) and HER-2/neu, through paracrine and autocrine mechanisms, may contribute to the proliferation and growth of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21302606     DOI: 10.1177/030089161009600501

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells.

Authors:  Ying Li; Li Shi; Chun Han; Yishang Wang; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2012-04-14

Review 2.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06

Review 3.  Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.

Authors:  Roberto Ronca; Patrizia Benzoni; Angela De Luca; Elisabetta Crescini; Patrizia Dell'Era
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

4.  Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.

Authors:  Antonio Aversa; Davide Francomano; Andrea Lenzi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-16       Impact factor: 5.555

Review 5.  Molecular and cellular mechanisms of castration resistant prostate cancer.

Authors:  Yiqiao Huang; Xianhan Jiang; Xue Liang; Ganggang Jiang
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.